Resistin, an adipokine, may affect the improvement of insulin sensitivity in the metabolic syndrome patient treated with metformin

Medical Hypotheses

Volumn 81, Issue 6, 2013, Pages 969-971

  Yuan, Hong ^a   Weng, Chunyan ^a   Yang, Youbo ^a   Huang, Lihua ^a   Xing, Xiaowei ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; METFORMIN; PIOGLITAZONE; RESISTIN; ROSIGLITAZONE; SULFONYLUREA;

ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; HUMAN; HYPOTHESIS; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS;

HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; METFORMIN; MODELS, BIOLOGICAL; RESISTIN; THIAZOLIDINEDIONES;

EID: 84888428114     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.08.014     Document Type: Article

References (28)

1. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific statement. Circulation 2005, 112:2735-2752.
2. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 2007, 86:836-842.
3. Gami A.S., Witt B.J., Howard D.E., et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007, 49:403-414.
4. Kulenović I. Impact of rosiglitazone on glycaemic control, insulin levels and blood pressure values in patients with type 2 diabetes. Med Arch 2006, 60:179-181.
5. Goldman-Levine J.D. Beyond metformin: initiating combination therapy in patients with type 2 diabetes mellitus. Pharmacotherapy 2011, 31(Suppl):44S-53S.
6. Zhang B.B., Zhou G., Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 2009, 9:407-416.
7. Towler M.C., Hardie D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007, 100:328-341.
8. Kahn S.E., Lachin J.M., Zinman B., et al. ADOPT Study Group. Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. Diabetes 2011, 60:1552-1560.
9. Fujita H., Fujishima H., Morii T., et al. Effect of metformin on adipose tissue resistin expression in db/db mice. Biochem Biophys Res Commun 2002, 298(3):345-349.
10. Lamanna C., Monami M., Marchionni N., Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2011, 13:221-228.
11. Kahn S.E., Haffner S.M., Heise M.A., et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
12. Yang Y.B., Liu H.X., Zhang Y., et al. Clinical observation of the effects of metformin on old patients with the metabolic syndrome and its effects on tumor necrosis factor-αand resistin influence. Chin J Geriatr 2007, 26:926-927.
13. Lee J.O., Lee S.K., Jung J.H., et al. Metformin induces Rab4 through AMPK and modulates GLUT4 translocation in skeletal muscle cells. J Cell Physiol 2011, 226:974-981.
14. Towler Mhairi.C., Grahame Hardie D. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007, 100:328-341.
15. Brunmair B., Staniek K., Gras F., et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?. Diabetes 2004, 53:1052-1059.
16. Zou M.H., Kirkpatrick S.S., Davis B.J., et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem 2004, 279:43940-43951.
17. Muse E.D., Obici S., Bhanot S., et al. Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest 2004, 114:232-239.
18. Luo Z., Zhang Y., Li F., et al. Resistin induces insulin resistance by both AMPK-dependent and AMPK-independent mechanisms in HepG2 cells. Endocrine 2009, 36:60-69.
19. Steppan C.M., Wang J., Whiteman E.L., Birnbaum M.J., Lazar M.A. Activation of SOCS-3 by resistin. Mol Cell Biol 2005, 25:1569-1575.
20. Barnes K.M., Miner J.L. Role of resistin in insulin sensitivity in rodents and humans. Curr Protein Pept Sci 2009, 10:96-107.
21. Yao H., Lin H., Wang Y., et al. Effects of metformin on glucose metabolism and serum lipogenic hormones in obese hyperinsulinemic children. Chin J Pract Pediatr 2007, 22(3):186-188.
22. Jung H.S., Youn B.S., Cho Y.M., et al. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism 2005, 54(3):314-320.
23. Kim H.J., Kang E.S., Kim D.J., et al. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2007, 66(2):282-289.
24. Gómez-Díaz R.A., Talavera J.O., Pool E.C., et al. Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial. Metabolism 2012, 61(9):1247-1255.
25. Vandewalle B., Moerman E., Lefebvre B., et al. PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets. Biochem Biophys Res Commun 2008, 366:1096-1101.
26. Lupi R., Del Guerra S., Fierabracci V., et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 2002, 51(Suppl. 1):S134-S137.
27. Steppan C.M., Bailey S.T., Bhat S., et al. The hormone resistin links obesity to diabetes. Nature 2001, 409(6818):307-312.
28. Goldman-Levine J.D. Beyond metformin: initiating combination therapy in patients with type 2 diabetes mellitus. Pharmacotherapy 2011, 31(12 Suppl):44S-53S.